Aubagio from Genzyme/Sanofi is filed at FDA for relapsing Multiple Sclerosis

Genzyme/Sanofi announced that the FDA has accepted for review the new drug application (NDA) for oral teriflunomide (Aubagio) as a potential therapy for people with relapsing forms of multiple sclerosis (MS). Sanofi expects to file an application for regulatory approval with the European Medicines Agency (EMA) in the first quarter of 2012.